Sales & Marketing Deep Dive: Commercialisation 2024 In this issue, we unpack Ozempic’s rise to superstar status and the risks associated with its off-label use.
News Taiho's late-stage Duchenne candidate fails trial Taiho has suffered a blow to its near-term pipeline after a drug candidate for Duchenne muscular dystrophy (DMD) missed the mark in a phase 3 trial.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
